Serious Asthma Outcomes and Asthma Exacerbations with Maintenance on Inhaled Corticosteroid (Mometasone Furoate)/Long-Acting Beta Agonist (Formoterol) Combination Compared to Step Down to Mometasone Monotherapy

Chowdhury, 2010, The FDA and safe use of long-acting beta-agonists in the treatment of asthma, N Engl J Med, 362, 1169, 10.1056/NEJMp1002074 Weinstein, 2019, Serious asthma events with mometasone furoate plus formoterol compared with mometasone furoate, J Allergy Clin Immunol, 143, 1395, 10.1016/j.jaci.2018.10.065 Stempel, 2016, Serious asthma events with fluticasone plus salmeterol versus fluticasone alone, N Engl J Med, 374, 1822, 10.1056/NEJMoa1511049 Stempel, 2016, Safety of adding salmeterol to fluticasone propionate in children with asthma, N Engl J Med, 375, 840, 10.1056/NEJMoa1606356 Peters, 2016, Serious asthma events with budesonide plus formoterol vs. budesonide alone, N Engl J Med, 375, 850, 10.1056/NEJMoa1511190 Lemanske, 2010, The US Food and Drug Administration and long-acting beta2-agonists: the importance of striking the right balance between risks and benefits of therapy?, J Allergy Clin Immunol, 126, 449, 10.1016/j.jaci.2010.05.039 Brozek, 2012, Long-acting β2-agonist step-off in patients with controlled asthma. Systematic review with meta-analysis, Arch Intern Med, 172, 1365, 10.1001/archinternmed.2012.3250 Juniper, 1999, Development and validation of a questionnaire to measure asthma control, Eur Respir J, 14, 902, 10.1034/j.1399-3003.1999.14d29.x Bateman, 2006, Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down, J Allergy Clin Immunol, 117, 563, 10.1016/j.jaci.2005.11.036 Koenig, 2008, Deterioration in asthma control when subjects receiving fluticasone propionate/salmeterol 100/50 mcg diskus are “stepped-down”, J Asthma, 45, 681, 10.1080/02770900802168695 Godard, 2008, Maintaining asthma control in persistent asthma: comparison of three strategies in a 6-month double-blind randomised study, Respir Med, 102, 1124, 10.1016/j.rmed.2008.03.014 Reddel, 2010, Down-titration from high-dose combination therapy in asthma: removal of long-acting b2-agonist, Respir Med, 104, 1110, 10.1016/j.rmed.2010.04.003 O’Hagan, 2012, Loss of asthma control in pediatric patients after discontinuation of long-acting beta-agonists, Pulm Med, 2012, 894063 Slankard, 2016, Impact of the Arg 16 allele of the B2AR gene on the effect of withdrawal of LABA in patients with moderate to severe asthma, J Asthma, 53, 783, 10.3109/02770903.2016.1161049 Adachi, 2016, Efficacy and safety comparison: fluticasone furoate and fluticasone propionate, after step down from fluticasone furoate/vilanterol in Japanese patients with well-controlled asthma, a randomized trial, Respir Med, 120, 78, 10.1016/j.rmed.2016.09.018 Horiuchi, 2016, Step-down therapy in well-controlled asthmatic patients using salmeterol xinafoate/fluticasone propionate combination therapy, J Asthma Allergy, 9, 65, 10.2147/JAA.S93782 Mori, 2016, Step-down treatment from medium-dosage of budesonide/formoterol in controlled asthma, Respir Med, 119, 1, 10.1016/j.rmed.2016.08.007 Ahmad, 2015, Stopping long-acting beta2-agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids (Review), Cochrane Database Syst Rev, CD011306 Maxwell, 2005, Beta-2 adrenergic receptor genotypes and haplotypes in different ethnic groups, Int J Mol Med, 16, 573 Bleecker, 2010, Beta2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate, Am J Respir Crit Care Med, 181, 676, 10.1164/200809-1511OC Finkelstein, 2009, Polymorphism of the ADRB2 gene and response to inhaled beta-agonists in children with asthma: a meta-analysis, J Asthma, 46, 900, 10.3109/02770900903199961 Israel, 2004, Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial, Lancet, 364, 1505, 10.1016/S0140-6736(04)17273-5 Peters, 2007, Real-world Evaluation of Asthma Control and Treatment (REACT): findings from a national web-based survey, J Allergy Clin Immunol, 119, 1454, 10.1016/j.jaci.2007.03.022 Eisner, 2001, Risk factors for hospitalization among adults with asthma: the influence of sociodemographic factors and asthma severity, Respir Res, 2, 53 Juniper, 2004, Measuring health-related quality of life in adults during an acute asthma exacerbation, Chest, 125, 93, 10.1378/chest.125.1.93 Tierney, 2004, Assessing symptoms and peak expiratory flow rate as predictors of asthma exacerbations, J Gen Intern Med, 19, 237, 10.1111/j.1525-1497.2004.30311.x Kim, 2009, Factors associated with severity and exacerbation of asthma: a baseline analysis of the cohort for reality and evolution of adult asthma in Korea (COREA), Ann Allergy Asthma Immunol, 103, 311, 10.1016/S1081-1206(10)60530-3